AAHomecare engages Dobson Davanzo for NIV study
By HME News Staff
Updated 1:32 PM CDT, Thu July 11, 2024
WASHINGTON – AAHomecare is leading an effort to quantify the differences in outcomes and overall treatment costs for patients with significant respiratory challenges who receive non-invasive ventilation (NIV) therapy versus those who don’t. The research will help to determine the benefits of this therapy using CMS’s own data, potentially providing authoritative data to underpin advocacy to strengthen patient access to NIV, the association says. “This important effort stems from discussions at last year’s Board Strategic Planning Session on how we can limit delays and denials for patients who can benefit from NIV,” said Tom Ryan, AAHomecare president & CEO “Our leaders believe this is an area where credible data on outcomes and overall costs will make a strong impression on policymakers and payers.” AAHomecare has engaged Dobson Davanzo & Associates to conduct research and analyze results. They will involve respiratory stakeholders, including clinicians and HME industry experts, to further develop cohorts and provide oversight. The association says work will begin next week, and the project is expected to be completed in about 10 months.
-
This research is the latest effort by stakeholders to curb denial rates for NIV. They have also partnered with patient advocacy groups like the ALS Association to ask CMS to clarify policy and coverage.
Comments